In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include: Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. Gradishar Therapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. Abraham Addressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. Spring Presenters: Jame Abraham, MD, FACP Enterprise Chair and Professor of Medicine Department of Hematology and Medical Oncology Cleveland Clinic Cleveland, Ohio William J. Gradishar, MD, FACP, FASCO Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago, Illinois Laura Spring, MD Breast Medical Oncologist Mass General Hospital Cancer Center Harvard Medical School Boston, Massachusetts Link to full program including downloadable slides and on-demand webcasts: https://bit.ly/4b5GFqq To claim credit for listening to this episode, please visit the podcast online at the link above. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
